Group 1 - The core point of the article is that Jieya Co., Ltd. (301108) reported a total of 7,164 shareholders as of January 9, 2026 [1]

Market Overview - The personal care products sector experienced a slight decline of 0.03% on January 13, with Baiya Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Stock Performance - Notable gainers in the personal care sector included: - Dengkang Oral Care (001328) with a closing price of 40.60, up 6.17% [1] - Beijia Clean (603059) with a closing price of 36.25, up 3.93% [1] - Jieya Co., Ltd. (301108) with a closing price of 35.95, up 3.72% [1] - Other stocks showed mixed performance, with some experiencing declines, such as: - Two-Sided Needle (600249) down 0.67% to 5.92 [1] - Zhongshun Jiesang (002511) down 0.95% to 8.32 [1] Capital Flow - The personal care products sector saw a net inflow of 17.19 million yuan from institutional investors, while retail investors experienced a net outflow of 20.21 million yuan [2] - The capital flow for individual stocks indicated that: - Reliable Co., Ltd. (301009) had a net inflow of 10.73 million yuan from institutional investors [3] - Beijia Clean (603059) faced a net outflow of 3.99 million yuan from institutional investors [3]

证券代码：301108 证券简称：洁雅股份 公告编号：2026-001 铜陵洁雅生物科技股份有限公司 关于全资子公司完成工商变更登记并换发营业执照的公告 名称：安徽洁创医疗器械有限公司 经营范围：许可项目：第二类医疗器械生产；第三类医疗器械的生产；第三 类医疗器械的经营；卫生用品和一次性使用医疗用品生产（依法须经批准的项目， 经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可 证件为准） 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 铜陵洁雅生物科技股份有限公司（以下简称"公司"）于近日收到全资子公 司安徽洁创医疗器械有限公司（以下简称"洁创医疗"）的通知，根据经营发展 需要，洁创医疗对其住所进行了变更，已完成相关工商变更登记及备案手续，并 取得了铜陵市铜官区市场监督管理局换发的《营业执照》。相关信息如下： 二、变更后的营业执照基本情况 统一社会信用代码：91341321MA8PWDRU15 类型：有限责任公司（自然人投资或控股的法人独资） 法定代表人：蔡英传 注册资本：伍佰万圆整 成立日期：2023年01月05日 住所：安徽省铜陵市铜官 ...

Group 1 - The core viewpoint of the article is that Jieya Co., Ltd. (301108) is currently in the equipment installation and debugging phase for its factory in the United States, with production expected to officially commence in the second half of this year [1]

Group 1 - The core viewpoint of the article is that Jieya Co., Ltd. has completed land acquisition in Egypt, which is aimed at expanding its global market presence outside the United States [1] - The acquired land is primarily planned for development to enhance the company's international market coverage [1] - The project is currently in the early planning stage, and further updates will be provided through official company announcements [1]

Core Viewpoint - The company, Jieya Co., announced that its factory in the United States is currently in the equipment installation and debugging phase, with production expected to officially commence in the second half of 2026 [1] Group 1 - The U.S. factory will primarily employ local American workers once it is operational [1]

21智讯01月12日电，洁雅股份在投资者关系活动中表示，公司已在埃及完成土地购置，该地块主要用于 拓展和覆盖美国以外的全球市场。目前该项目仍处于前期规划阶段，后续进展将依据公司公告披露。 ...

Market Overview - The personal care products sector increased by 1.28% on January 12, with Beijia leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up by 1.09%, while the Shenzhen Component Index closed at 14366.91, up by 1.75% [1] Stock Performance - Beijia (603059) closed at 34.88, with a rise of 10.00% and a trading volume of 21,500 lots, resulting in a transaction value of 74.26 million yuan [1] - Haoyue Care (605009) closed at 32.52, up by 2.59%, with a trading volume of 38,600 lots and a transaction value of 124 million yuan [1] - Reliable Co. (301009) closed at 13.11, increasing by 1.55%, with a trading volume of 47,100 lots and a transaction value of 61.36 million yuan [1] - Other notable stocks include: - Wenjian Medical (300888) at 39.73, up by 1.43% [1] - Runben Co. (603193) at 25.33, up by 1.40% [1] - Liangmian Needle (600249) at 5.96, up by 1.36% [1] Capital Flow - The personal care products sector experienced a net outflow of 1.1334 million yuan from institutional investors, while retail investors saw a net inflow of 5.4803 million yuan [2] - The overall capital flow indicates that while institutional investors withdrew funds, retail investors were actively buying into the sector [2] Detailed Capital Flow Analysis - Beijia (603059) had a net inflow of 23.84 million yuan from institutional investors, but a net outflow of 9.50 million yuan from speculative funds [3] - Haoyue Care (605009) saw a net inflow of 18.45 million yuan from institutional investors, with a net outflow of 12.29 million yuan from speculative funds [3] - Reliable Co. (301009) experienced a net outflow of 5.92 million yuan from institutional investors, while retail investors contributed a net inflow of 6.46 million yuan [3]

Company Overview - Tongling Jeya Biotechnology Co., Ltd. was established in 1999 and specializes in the research, production, and sales of wet wipes, accumulating over 20 years of industry experience [2]. - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on December 3, 2021 [2]. Financial Performance - For the first three quarters of 2025, the company reported a revenue of 5.65 billion CNY and a net profit of 6,790.31 million CNY [2]. Q&A Highlights Production and Expansion - The U.S. factory is currently in the equipment installation and debugging phase, expected to commence production in the second half of this year [2]. - Land has been purchased in Egypt for future expansion to cover global markets outside the U.S., with the project still in the early planning stages [3]. Mergers and Acquisitions - The company is actively seeking quality acquisition targets that can create synergies with existing operations and add substantial value for long-term growth [3]. Product Lines and Market Strategy - There are no significant planned investments in the collagen business at this time [3]. - The performance of personal care products is currently limited in order volume, but customer expansion efforts are ongoing [3]. - The company's core competitive advantages lie in its long-term focus on the wet wipes market, with strengths in technology R&D, production processes, quality control, customer resources, and product variety [3]. Future Growth Prospects - Future growth is expected to come from deepening collaborations with existing international brand clients and expanding product categories and sales regions, as well as leveraging new market opportunities and localized supply chain advantages from the U.S. factory [3]. Compliance and Governance - The company adhered to the Shenzhen Stock Exchange's regulations during the investor communication event, ensuring no significant undisclosed information was leaked [3].

Market Overview - The personal care products sector increased by 0.64% on January 9, with Dengkang Oral leading the gains [1] - The Shanghai Composite Index closed at 4120.43, up 0.92%, while the Shenzhen Component Index closed at 14120.15, up 1.15% [1] Stock Performance - Key stocks in the personal care sector showed varied performance, with Dengkang Oral closing at 39.19, up 1.79% on a trading volume of 15,000 shares and a transaction value of 58.84 million yuan [1] - Other notable performers included: - Zhongshun Jierou at 8.38, up 1.09%, with a trading volume of 164,500 shares and a transaction value of 137 million yuan [1] - Wanjian Medical at 39.17, up 1.03%, with a transaction value of 166 million yuan [1] - Liangmian Needle at 5.88, up 1.03%, with a trading volume of 119,500 shares and a transaction value of 69.76 million yuan [1] Capital Flow - The personal care products sector experienced a net outflow of 9.1265 million yuan from institutional investors and 14.5833 million yuan from speculative funds, while retail investors saw a net inflow of 23.7098 million yuan [2] - Detailed capital flow for specific stocks included: - Runben Co. with a net inflow of 4.5229 million yuan from institutional investors, but a net outflow of 6.0816 million yuan from speculative funds [3] - Yiyi Co. had a net outflow of 51,000 yuan from institutional investors, but a net inflow of 619.27 million yuan from retail investors [3] - Dengkang Oral saw a net outflow of 1.5334 million yuan from institutional investors [3]